Survival up after progression in HPV-positive oropharynx CA

June 26, 2014
Survival up after progression in HPV-positive oropharynx CA

(HealthDay)—For patients with oropharynx cancer (OPC), human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study published online June 23 in the Journal of Clinical Oncology.

Carole Fakhry, M.D., from Johns Hopkins Medical Institutions in Baltimore, and colleagues examined the risk of death after progression for with HPV-positive OPC relative to HPV-negative OPC. Data were collected for patients with stage III to IV OPC, enrolled onto Radiation Therapy Oncology Groups (RTOG) trial 0129 or RTOG 0522. The cohort comprised 181 patients with OPC, including 105 with p16-positive and 76 with p16-negative tumors.

The researchers found that patients with p16-positive and p16-negative tumors had similar patterns of failure and median time to progression. Patients with p16-positive OPC had significantly improved survival rates after a median follow-up of four years, compared with p16-negatve patients (two-year overall survival, 54.6 versus 27.6 percent; median, 2.6 versus 0.8 years; P < 0.001). After adjustment for tumor stage and cigarette pack-years at enrollment, the risk of death after was reduced with p16-positive tumor status (hazard ratio, 0.48) and receipt of salvage surgery (hazard ratio, 0.48) and was increased with distant versus locoregional progression (hazard ratio, 1.99).

"Tumor HPV status is a strong and independent predictor of overall after disease progression and should be a stratification factor for clinical trials for patients with recurrent or metastatic OPC," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, including Bristol-Myers Squibb, which partially funded the study.

Explore further: In oropharyngeal cancer, HPV status impacts distant mets risk

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

In oropharyngeal cancer, HPV status impacts distant mets risk

January 14, 2013

(HealthDay)—In patients with oropharyngeal cancer (OPC), human papillomavirus (HPV) status and T and N staging categories affect the rate of distant control (DC) and may help identify candidates for treatment deintensification ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.